In summary, transgenic models were first of their kind to validate the oncogenic potential of BCR-ABL and to support the expression of BCR-ABL as the prime initiating event for CML induction by p190 BCR-ABL [29]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.